IVIG Privigen denied as experimental or investigational by Humana?

Humana's specific coverage criteria for ivig privigen are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Privigen (IVIG) as Experimental or Investigational

Humana's experimental/investigational denial for Privigen (immune globulin intravenous, human — 10%) almost always means that IVIG is being prescribed for an indication that Humana's clinical policy does not list as a covered, evidence-based use — not that Privigen itself lacks FDA approval. Humana, like other large insurers, maintains a list of approved IVIG indications; conditions not on that list are classified as experimental regardless of whether physicians routinely use IVIG for them in clinical practice. The specific indication driving this denial is the critical fact to identify.

## Why This Denial Is Appealable

An experimental/investigational determination must be based on the current state of medical evidence for your specific condition, not simply on whether the use appears in Humana's internal policy list. Medical societies such as the American Academy of Neurology, the American Academy of Allergy, Asthma & Immunology, and others have published guidelines supporting IVIG for a range of conditions beyond the most common FDA-approved indications. If your prescriber can cite the applicable guideline organization and document that your case meets its criteria, you have a strong basis to argue the use is not experimental by any legitimate evidence standard. Humana is also required to explain, in the denial, why it considers the evidence insufficient — and that reasoning can be challenged.

## Your Federal Appeal Rights

• Internal appeal: ACA §2719 and ERISA §503 guarantee a full-and-fair internal review. File within the deadline on your denial notice.
• External review: Experimental/investigational denials are specifically subject to independent external review. An IRO with clinical expertise in your condition will evaluate the evidence independently. The external-review window is typically around four months from the final adverse determination. Expedited review is available when delay would seriously jeopardize health.

## Concrete Appeal Steps and Timeline

1. Identify the exact indication for which Privigen is prescribed — this must appear prominently in the appeal. 2. Obtain Humana's current IVIG medical policy and identify where your indication falls relative to Humana's approved-uses list. 3. Have the prescribing specialist write a detailed medical-necessity letter that (a) cites the applicable professional-society guideline by name, (b) explains the evidence supporting IVIG for your indication, and (c) documents how your case meets the guideline's criteria. 4. Submit a peer-reviewed literature summary supporting the indication if the prescriber can provide one. 5. File the internal appeal, then immediately prepare for external review if the internal appeal is denied.

## Documentation to Gather

• Diagnosis records confirming the specific condition for which IVIG is indicated
• Specialist letter referencing the applicable guideline organization and documenting clinical severity
• Treatment history showing prior therapies attempted, with dates and outcomes
• Relevant diagnostic workup records
• Any peer-reviewed literature your prescriber identifies as supporting the indication (do not fabricate citations — use only what your physician provides)

## Criteria-Mapping Structure

Obtain Humana's IVIG policy coverage criteria. List each criterion. For each, pair it with the exact chart fact or physician statement that satisfies it. For any "experimental" finding, document the specific professional society guideline that supports the use and the chart evidence that places your case within that guideline's scope.